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Abstract: Since the clear demonstration of lysophosphatidic acid (LPA)’s pathological roles in cancer
in the mid-1990s, more than 1000 papers relating LPA to various types of cancer were published.
Through these studies, LPA was established as a target for cancer. Although LPA-related inhibitors
entered clinical trials for fibrosis, the concept of targeting LPA is yet to be moved to clinical cancer
treatment. The major challenges that we are facing in moving LPA application from bench to bedside
include the intrinsic and complicated metabolic, functional, and signaling properties of LPA, as well
as technical issues, which are discussed in this review. Potential strategies and perspectives to
improve the translational progress are suggested. Despite these challenges, we are optimistic that
LPA blockage, particularly in combination with other agents, is on the horizon to be incorporated
into clinical applications.
Keywords: Autotaxin (ATX); ovarian cancer (OC); cancer stem cell (CSC); electrospray ionization
tandem mass spectrometry (ESI-MS/MS); G-protein coupled receptor (GPCR); lipid phosphate
phosphatase enzymes (LPPs); lysophosphatidic acid (LPA); phospholipase A2 enzymes (PLA2s);
nuclear receptor peroxisome proliferator-activated receptor (PPAR); sphingosine-1 phosphate (S1P)
1. Introduction
Lysophosphatidic acids (LPAs) are simple lipids, but they are involved in virtually every aspect
of tumor development, covering all 10 cancer hallmark activities [1–7]. They include, but are not
limited to, stimulation of the proliferative signaling [8–10], evading growth suppressors and resisting
cell death by regulating the apoptotic and other cell death/survival pathways [11,12], enabling
replicative immortality by regulating telomerase [13], inducing angiogenesis and lymphangiogenesis
via upregulation of proangiogenic factors, such as vascular endothelial growth factor A (VEGFA),
vascular endothelial growth factor C (VAGFC), interleukin (IL)-1β [14–18] and IL-8 [19–21], and
activating invasion and metastasis [22–26]. In addition, LPA affects genome instability (the autotaxin
(ATX)-LPA axis is involved in reactive oxygen species (ROS)-induced genomic instability [27] and
γ-irradiation-induced DNA damage repair [28], inflammation by regulating inflammatory factors,
such as cyclooxygenase-2 (COX2), IL6, and Tumor necrosis factor-alpha (TNFα) [29–31]) and energy
metabolism (ATX–LPA signaling contributes to obesity-induced insulin resistance [32]; LPA triggers
glycolytic shift and induces metabolic reprogramming in ovarian cancer via Rac-mediated activation
of nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) and generation of reactive
oxygen species (ROS), resulting in activation of hypoxia inducible factor 1-alpha (HIF1α) [33] and
the immune system [1–7,34]). In particular, expression of ATX or each of the endothelial-derived
G-protein–coupled receptor (EDG)-family LPA receptor (LPAR) (LPAR1–3) in the mammary epithelium
of transgenic mice was shown to be sufficient to induce breast cancer [26]. The current review does not
cover these functions or signaling pathways in detail, but rather focuses on the issues pertinent to the
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translation of LPA targeting to clinic applications. The different aspects of LPA’s functions in cancer
were extensively reviewed over several decades [3–5,7,21,35–49].
The major challenges in moving LPA targeting to clinical practice include the complex metabolic
network of LPA, the extremely broad and multifaceted pathological activities elicited by LPA, which
are overlapping with its physiological activities, the complicated and potentially opposing cellular
activities mediated by different LPA receptors in an individual cancer and individual patient-dependent
manner, and the maze of intertwined G-protein coupling and downstream signaling pathway elicited
by LPA through its own receptors, as well as many other types of cell receptors and signaling pathways.
Moreover, technical issues for LPA detection and/or blockage, as well as study design issues are also
major obstacles to overcome. This review focuses on these issues with perspectives to improve the
LPA translational progress.
2. LPA: From Bench to Bedside
2.1. A Brief History and Milestones of LPA Research
2.1.1. Before the Identification of LPA Receptors
LPA was first described in the early 1960s [50,51]. It was later studied in almost all type of
cells in organisms ranging from bacteria to plants to animals. In the 1960s, only eight papers were
published related to LPA. This number increased to ~40, ~100, and ~300 in the 1970s, 1980s, and 1990s,
respectively. At the turn of the century, the number of LPA-related studies increased exponentially
to more than 4000 papers related to LPA published since the year 2000 (Figure 1). Among these
LPA papers, ~1300 papers are related to cancer/tumor, covering almost all types of solid and blood
cancers/tumors (Figure 1). This list includes, but is not limited to, cancers of ovarian, lung, gastric,
colorectal, breast, prostate, bladder, endometrial, renal, oral, pancreatic, cervical, and brain (including
glioblastoma) origin, as well as leukemias, non-Hodgkin’s lymphomas, fibrosarcoma, osteosarcoma,
and melanoma [3,4,21,48,52]. Among these publications, ~20% of the papers are related to ovarian
cancer (OC) alone.
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Figure 1. Lysophosphatidic acid (LPA)-related papers published in decades and the milestones in 
LPA research. The blue bars are the total number of LPA-related papers published in each decade. 
The orange bars are the numbers of LPA studies related to cancer. The pink circled numbers are 
milestones related to LPA research in general, and the green circled numbers are cancer-related 
milestones. (1) LPA’s mitogen and growth factor like activity, as well as G-protein-mediated signaling 
mechanisms were discovered in the late 1980s and early 1990s [35,53–59]. (2) In 1995, the pathological 
significance of LPA in cancer was first reported [8–10]. (3) From 1996 to 2009, six LPA G-protein 
coupled receptors (GPCRs) were identified and cloned [60–71]. (4) From 1998 to the present, LPA as 
a putative cancer marker was reported [22,72–82]. (5) From 2000 to the present, new technologies, 
including the electrospray ionization tandem mass spectrometry (ESI-MS/MS) methods, were 
developed for LPA analyses [73,83–87]. In addition, LPA antibodies were developed and further 
improved. In 2008, Lpath Inc. successfully humanized an anti-LPA antibody. (6) In 2002, the major 
Figure 1. Lysophosphatidic aci ( P )-relate papers published in decades and the milestones in
LPA research. The blue bars are the total nu ber of LP -related papers published in each decade.
The orange bars are the numbers of LPA studies related to cancer. The pink circled numbers are
milestones related to LPA research in general, and the green circled numbers are cancer-related
milestones. (1) LPA’s mitogen and growth factor like activity, as well as G-protein-mediated signaling
mechanisms were discovered in the late 1980s and early 1990s [35,53–59]. (2) In 1995, the pathological
significance of LPA in cancer was first reported [8–10]. (3) From 1996 to 2009, six LPA G-protein coupled
receptors (GPCRs) were identified and cloned [60–71]. (4) From 1998 to the present, LPA as a putative
cancer marker was reported [22,72–82]. (5) From 2000 to the present, new technologies, including the
electrospray ionization tandem mass spectrometry (ESI-MS/MS) methods, were developed for LPA
analyses [73,83–87]. In addition, LPA antibodies were developed and further improved. In 2008, Lpath
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Inc. successfully humanized an anti-LPA antibody. (6) In 2002, the major LPA-producing enzyme ATX
was identified and cloned [88,89]. (7) From 2011 to 2017, ATX and LPA G-protein coupled receptors
(GPCRs) were crystalized with their structures determined [90–94]. (8) From 2013 to the present,
FDA-approved ATX and LPA receptor (LPAR) inhibitors entered clinical trials for fibrosis [95].
LPA was first isolated from brain extracts in 1961 [50]. Most studies on LPA at the early stage
(from 1960s to 1970s) focused on the biochemical analyses of LPA, including enzymes involved in LPA
metabolism and catabolism, as well as the tissue, cellular, and sub-cellular locations of LPA. Several
of these studies are structure–activity studies, as LPA is a group of more than 20 molecules, varying
in their fatty-acid chain location (sn-1 vs. sn-2 on the glycerol backbone), the numbers of carbons in
the fatty-acid chain, the number and location of the double bonds in the fatty-acid chain, and also the
chemical linkage between the fatty acid and the glycerol (ether linkage vs. ester linkage) [96–98].
The 1980s were the beginning decade for extensive functional and signaling studies of LPA.
LPA-induced platelet aggregation and alterations in arachidonate metabolism were the earliest LPA
functions revealed, which were further studied over the following decades [31,96,99–104]. The effects
of LPA on ion channels were noticed as early as the 1980s [98] and regained more interest in recent
years [98,105–110]. The intravenous injection of LPA induces hypertension in animals [97,111–113].
The mitogen (cell proliferation) activity of LPA was discovered in the late 1980s and early 1990s,
before the molecular cloning of LPA receptors [35,53–56]. In addition, the potent effects of LPA
on cell skeleton-related activities were reported in various cell types and/or organisms even before
its receptors were identified/cloned in 1996. LPA induces contraction of rat isolated colon [114],
reverts the β-adrenergic agonist-induced morphological response in C6 rat glioma cells [115], induces
neuronal shape changes [57], and is a chemoattractant for Dictyostelium discoideum amoebae and
human neutrophils [58,116]. Moreover, LPA inhibits gap-junctional communication and stimulates
phosphorylation of connexin-43 in while blood cells. Focal adhesion kinase (FAK), paxillin, and p130
are important LPA-targeting genes/proteins [117–119].
In terms of signaling properties, calcium and cyclic adenosine monophosphate (cAMP) are
the earliest revealed downstream signaling molecules for LPA [120]. Its regulation of protein
phosphorylation was also discovered [117–119,121]. One of the milestone papers for LPA signaling
published by Moolenaar’s group in the late 1980s showed that LPA initiates at least three separate
signaling cascades: activation of a pertussis toxin-insensitive G-protein mediating phosphoinositide
hydrolysis with subsequent Ca2+ mobilization and stimulation of protein kinase C; release of arachidonic
acid in a guanosine triphosphate (GTP)-dependent manner, but independent of prior phosphoinositide
hydrolysis; and activation of a pertussis toxin-sensitive Gi-protein mediating inhibition of adenylate
cyclase [53]. Later, the same group of investigators identified Ras activation as an important downstream
signaling pathway for LPA in fibroblasts [59,119]. Another important finding is that the cell skeleton
effects of LPA are linked to the small GTP-binding protein Rho [122].
The implications of the potential roles of LPA in cancer stem from the findings for LPA’s mitogen-
and growth factor-like activity in the late 1980s and early 1990s [35,53–59]. However, the majority of
these studies were conducted in model cellular systems (mainly in fibroblasts). In 1995, in searching for
the “ovarian growth factor” in human ascites from ovarian cancer patients, Xu et al. published three
seminal papers linking pathologic LPA to cancer (breast and ovarian cancer cells, as well as leukemia
cells) [8–10]. Since then, the research on the relevance of LPA in cancer and human health is booming
(Figure 1).
2.1.2. Post Identification of LPA Receptors
Although G-protein-mediated LPA signaling pathways were identified as described above,
molecular identification and cloning of LPA receptors in 1996 and the following years established the
corner stones for rapid growth of LPA-related studies and targeting, as G-protein coupled receptors
(GPCRs) represent targets for ~40% of pharmacological drug antagonists [123].
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The first LPA receptor was identified and cloned in 1996 [60], which was followed by
cloning and identification of a total of six LPA receptors, namely LPAR1/EDG2, LPAR2/EDG4,
LPAR3/EDG7, LPAR4/purinergic G protein-coupled receptor P2Y9 (P2Y9/GPR23, LPAR5/GPR92,
and LPAR6/P2Y5 [61–71]. Several additional G-protein coupled receptors (GPCRs) were also shown to
be putative LPA receptors, including GPR87 [124,125], GPR35 [126], and P2Y10 [127]. However,
they are less studied and/or not confirmed as LPA receptors. Moreover, the nuclear receptor
peroxisome proliferator-activated receptor gamma (PPARγ) was identified as an intracellular LPA
receptor [128–131]. PPARγ belongs to the nuclear receptor superfamily of PPARs (PPARα, PPARβ/δ,
and PPARγ). PPARs play a role in inflammation and a variety of cancers which include prostate, breast,
glioblastoma, neuroblastoma, pancreatic, hepatic, leukemia, and bladder and thyroid cancers [132],
and they are mainly studied by using their natural and synthetic agonists or antagonists, including
thiazolidinediones, different unsaturated fatty acids, and GW9662. The results are contradictory, with
both pro- and anti-tumor roles of PPARγ reported [132]. LPA was identified as a new ligand for PPARγ
in 2003 [60]. Until recently, LPA–PPARγ studies were mainly limited to the vascular and metabolic
processes [130]. We recently showed that LPA upregulates an oncogene ZIP4 in epithelial ovarian
cancer (EOC) cells, mainly via PPARγ, and LPA’s cancer stem cell (CSC)-promoting activities are
mediated by PPARγ [133].
Another important milestone in LPA research was the identification of the major LPA-producing
enzyme, autotaxin (ATX). Although the enzymatic activity of the lysophospholipase D in the production
of LPA was described earlier in rat plasma [134], the gene encoding this enzyme for this activity was
not known until 2002 [88,89].
The crystallization and structure determination for LPA GPCRs belonging to each of the two
subclasses (EDG and purinergic receptors), as well as ATX [90–94], in recent years were pivotally
important in design and development of anti-cancer reagents targeting them. In fact, Food and Drug
Administration (FDA)-approved inhibitors against ATX and LPA monoclonal antibody entered into
clinical trials for fibrosis [95] (Figure 1).
The functions/cellular effects of LPA (both physiological and pathological) are very broad, which
were extensively reviewed [3,35,36,135–138]. The signaling pathways, mainly those mediated by LPA
GPCR receptors, were also extensively studied and reviewed [3,35,61,135,136,138,139]. This review
focuses on the challenges in moving bench LPA studies to clinical practice (bedside).
2.2. Challenges and Obstacles of LPA Clinical Applications in Cancer
2.2.1. The Issues with LPA as a Marker for Cancer
We initially reported LPA as a potential marker for ovarian cancer (OC) [72], which is supported
by blinded [22] and numerous independent studies [73–81]. LPA was also shown to be a biomarker for
other gynecological cancers [72], as well as for gastric cancer [82].
However, we are facing several challenges in moving LPA as a cancer marker to clinical
application [7]. These issues are tightly related to the biochemical nature of LPAs, which are
metabolites, having a quick turnover time due to their producing and degradation enzymes, as well as
several other potential factors [7,81,140,141]. Many epidemiological factors, such as diet, smoking, and
drinking may also have significant effects on LPA levels detected, which are not always included in
various studies. Technical issues are another major concern. These issues include many different lipid
extraction, storage, and detection methods used, which may generate LPA artefacts [7,141].
The analytic methods for LPA were greatly advanced from earlier (1960–1990s) thin-layer
and high-performance liquid chromatography-based analyses [8,142,143] to modern electrospray
ionization tandem mass spectrometric (ESI-MS/MS) methods [73,83–87]. Another major technological
advancement in LPA detection and targeting is the development of antibodies against LPA. LPA is not
immunogenic, since all animal species produce LPA and LPA is very small (molecular weights ranging
from 400 to 500 Da), lacking structural specificity to elicit a specific immune response. Nevertheless,
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Lpath Inc. successfully developed monoclonal LPA antibodies via their proprietary technique, which
were used in research [144,145] and commercially available LPA enzyme-linked immunosorbent assay
(ELISA) detecting kits (e.g.; Echelon Biosciences, T-2800s). These methods, however, have a limitation
where it is not possible to distinguish individual LPA species as the ESI-MS/MS analysis does.
To overcome these obstacles, one possibility is to measure the levels of ATX, the key enzymes
producing LPA [88,89], such as in the case of breast cancer and follicular lymphoma [146,147]. However,
LPA levels are controlled by a complex array of enzymes and other conditions (see Section 2.2.2);
therefore, ATX levels may not always correlate well to LPA levels. For example, while LPA levels are
elevated in EOC [22,72–81], ATX levels are indifferent in control and EOC subjects [77,148].
It may be critical to develop more direct detection methods for LPA from human samples, such as
a drop of fingertip blood on a filter paper, to avoid effects derived from variations in lipid extraction
and storage conditions. Direct imaging/reporter-based methods may represent another direction to
bypass the sample handling related artefacts.
2.2.2. Targeting LPA Metabolism
As mentioned above, LPA represents a group of compounds varying in their chemical linkage to the
glycerol backbone, number of carbons, and number and location of double bonds, with their molecular
weights between 400 and 500 Da [61,149]. In addition, several chemically closely related compounds,
including sphigosine-1 phosphate (S1P) [7,21,150,151], cyclic phosphatidic acid (cPA) [152–155], and
platelet-activating factor (PAF) [156–158], as well as other lysophospholipids [7,21] share similar,
distinct, or opposing signaling and functions to LPA. While this review focuses on LPA, it is important
to note that these additional lipids and their strong intertwining metabolic/catabolic pathways and
interactions in function make targeting LPA much more complex and challenging [71].
LPA production and catabolism are controlled by a complex network of enzymes. Extracellular
LPA is mainly produced by ATX and soluble phospholipase A2 enzymes (sPLA2s) [159].
Other PLA2s [160–166] and lipid phosphate phosphatase enzymes (LPPs) [5,167,168] play important
roles in LPA generation and degradation, respectively. PLA2s are not only critical in generating the
substrates for ATX to produce LPA, but they also generate LPA directly by acting on phosphatidic acid
as its substrate [159–165]. To-date, among the 22 identified human PLA2s, at least 10 were studied in
cancer, with most of them being aberrantly expressed in cancer [160] (Figure 2).
LPPs are major LPA catabolic enzymes. By removing the phosphate from LPA, they
inactivate most of LPA’s biological effects [5,167,168]. Other LPA-related enzymes include several
mono- or diacylglycerol kinases (MAGs and DAGs) involved in generating intracellular pools
of LPA [126,169,170], and lysophospholipase transacylase (LLPT) or LPA acyltransferases (LPATs)
inactivating LPA by converting it to phosphatidic acid [171–173] (Figure 2).
While depletion of ATX is embryonically lethal, postnatal decreases in the expression of ATX or
LPPs produce little obvious phenotypic change, suggesting less toxicity is expected when targeting
these enzymes [95]. Inhibitors against ATX and LPA monoclonal antibody entered into clinical trials
for fibrosis, but are yet to do so for cancer [95]. Targeting LPPs was not tested clinically, although
in vitro and preclinical studies support their anti-cancer roles [95,174].
At any rate, the complex array of enzymes and their regulations in LPA metabolism is a major
obstacle in targeting LPA production. In addition, the enzymes shown in Figure 2 are also involved
in the metabolism of other lipid molecules, further complicating the overall outcome. For example,
ATX also generates cyclic phosphatidic acids (cPAs: naturally occurring analogs of LPA), which have
anti-proliferative and anti-tumor activities [175,176] (Figure 2).
This situation is further complicated with the involvement of the tumor microenvironment (TME),
which was recently reviewed extensively [7,95,135]. It was shown that ~40% of ATX in the body is
produced by adipocytes, and this is increased further by inflammation in obesity linked to insulin
resistance [95,177]. Cross-regulation of the immune/inflammation system, and the preferred adipose
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tissues for LPA production are emerging as critical targets for breast and multiple aggressive abdominal
cancers, including colon, ovarian, and pancreatic cancers [7,95].Cancers 2019, 11, x 6 of 25 
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2.2.3. Targeting LPA Receptors
GPCRs are the larg st superfamily of receptors, with the identification of 865 human GPCR
genes [178]. Compared to other plasma membrane receptor types with more specific ligand types,
including receptor tyrosine kinases (RTKs), integrins, and ion transporters, ligands of GPCR cover
very diverse chemicals, including amino acids, amine derivatives, peptides, proteins, lipid molecules,
mechanical stimuli, and even ions, such as Ca2+, protons, and photons [179]. GPCRs are involved
in almost all of the important physiological and many critical pathological processes. About 40%
of drugs on the market act on GPCRs as agonists or antagonists [123]. The majority of LPA’s
tumor-promoting activities are mediated by LPA GPCR receptors, naturally making them one of the
most important targets.
One of the challenges in targeting LPA GPCR receptors is their complex array of G-protein coupling,
resulting in multi-faceted outcomes. While most of the other individual GPCRs, including most of the
best-studied β-adrenergic receptors, neurotransmitter receptors, and sensor GPCRs (olfactory, taste,
and photosensory receptors) [180–184] couple to one or two specific types of trimeric G-protein, each
LPAR couples to multiple G-proteins [61]. Further studies after the review in 2014 [61] showed single
G-protein coupled LPAR6 and double G-protein coupled LPAR3 to couple to both G12/13 and Gi for
LPAR6 [185–187] and G13, in addition to Gq and Gi for LPAR3 [188,189] (Figure 3).
Of interest, Gs coupling is involved in many essential physiological functions, ranging from
cardiovascular effects mediated by adrenergic receptors to neurotransmission by dopamine and
serotonin receptors, various hormonal effects by hormone receptors, energy and inflammation
regulation mediated by purinergic receptors, and skin pigmentation regulation by melanocortin
receptors [184,190–197]. In particular, all olfactory GPCRs, which consist of ~40% of all GPCRs in
humans, are coupled to Gs [180,198]. However, Gs in general is involved in anti-cancer activities.
While tumor-promoting activities are more consistently associated with LPAR1–3, which are
all coupled to the Gi/Ras/MAPK pathway [61], LPAR4–6 predominantly show anti-tumor activities.
For example, in colon cancer cells, LPAR1 and LPAR6 positively and negatively regulate colony
formation, respectively [199]. LPAR4 reduces cell proliferation, motility, and invasiveness in head
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and neck squamous cells [200]. In pancreatic cancer cells, downregulation of LPAR4 and LPAR5
enhanced the cell motility and colony formation activities [201]. LPAR5 inhibited the cell motility
activity of sarcoma and endothelial cells [202]. These inhibitory effects are most likely associated with
the predominate ability of LPAR4–6-mediated cAMP elevation via Gs-coupling (such as in the case
of LPAR4 and LPAR6) or a potentially Gs-independent pathway to increase cAMP via LPAR5 [149].
Contradictory effects of LPAR5 were also shown to enhance cell proliferation and motility in rat lung
and liver cancer cells [203], which may be related to its ability to couple to Gq and/or G12/13 [61]. On the
other hand, the inhibitory effects of LPAR5 in cytotoxic T cells may actually have a pro-tumorigenic
effect [204] (Figure 3).
Many LPA GPCR receptor agonists and antagonists were developed [61]. However, most, if not
all, of them have cross-activities on more than one LPA receptor or other target [61], potentially
complicating the outcomes using these inhibitors. Different LPARs are differentially expressed in
different cancers and different individuals. In addition, the existence of non-GPCR LPA receptors, such
as PPARγ, also needs to be considered. Studies using inhibitors against LPAR1, LPAR1/3, ATX, and
LPA monoclonal antibodies recently entered clinical trials for fibrosis [95]. Cancer treatment using
these reagents may be expected in the near future. However, more specific targeting of the particular
tumor promoting LPAR(s) on an individual cancer and person-based manner is likely to be critical to
make this targeting clinically beneficial.
As mentioned above, there are many different species of LPAs, which have preferences to bind
to different LPA receptors. For example, LPAR3 preferentially binds to LPA with unsaturated fatty
acids [51,205]. In addition, LPA GPCR receptors were shown to have ligands in addition to LPAs.
For example, peptone (protein hydrolysates) and farnesyl pyrophosphate are agonists for LPAR5.
GPR35 is a receptor for a number of naturally occurring lipids, including kynurenic 2-arachidonoyl LPA
and lysophosphatidylinositol [126,149]. These issues are under-investigated, but may play significant
roles in clinical practice.
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2.2.4. Targeting LPA Cross-Talk
2.2.4.1. Cross-Talk between LPA Signaling and Other Cell Signaling Receptors
LPA elicits multiple and complex signaling pathways, which were extensively reviewed in recent
years [21,31,48,61,95,206–209]. LPA signaling pathways intertwine with almost all other major cell
signaling pathways. We postulate that this network, instead of an individual LPA signaling pathway,
represents a more effective target. Hence, this review focuses on LPA cross-talk with other signaling
molecules. These molecules are often more “targetable” with FDA-approved inhibitors in clinical trials.
The cross-talk between LPA and other signaling molecules was extensively demonstrated, covering
virtually every type of cell plasma membrane receptors, including ligand-gated ion channels, receptor
tyrosine kinases (RTKs), receptors with other enzymatic activities (serine or serine/threonine kinases
and guanylyl cyclase enzymatic activities), other GPCRs, integrins, cytokine receptors, and T- and
B-cell receptors, as well as intracellular receptors, such as PPARγ. Listed below are examples from
these categories (Figure 4).
LPA stimulates and regulates several ion channels, including the Ca2+ and Ca2+-activated
potassium channels, and the Na+/H+ exchanger 3 (NHE3) via the LPAR5 receptor, which also involves
the epidermal growth factor receptor (EGFR) [210,211]. LPA also regulates glucose transporters in
skeletal muscle and adipose tissue [212]. We recently showed that LPA upregulates ZIP4 (a zinc
transporter) expression mainly via PPARγ [133] (Figure 4).
The cross-talk between receptor tyrosine kinase (RTK)–GPCR signal complexes is a focal point for
the study of integration of cell signaling, which plays an important role in signal transduction [213].
The cross-talk between LPA and EGFR is the best studied [214–219]. LPA also regulates and/or
transactivates platelet derived growth factor receptor (PDGFR) [220–224], tropomyosin receptor kinase
A (TrkA), the receptors for nerve growth factor (NGF) [225], Toll-like receptors [226], and c-Met, the
receptor for hepatocyte growth factor [227].
LPA inhibits the natriuretic peptide-induced generation of cGMP via a non-receptor tyrosine
kinase Csk [228–230]. The best example of LPA’s effect on non-membrane receptors is its functions
with regard to Src family kinases [231–234]. In addition, LPA regulates cytokines, such as IL-6, and its
downstream signal transducers and activators of transcription (Stat) signaling molecules [235].
LPA interacts with other GPCR receptors. Free fatty-acid receptors (FFARs; FFA1 and
FFA4) have a potential negative cross-talk between LPA receptors and EGF receptors [217,236].
LPA stimulates endothelin (a GPCR ligand) expression and production in vascular smooth muscle
cells [237]. In addition, a cross-talk between the LPAR–G13/p115RhoGEF/RhoA pathway and the
β2-adrenergic receptor/Gs/adenylyl cyclase pathway was reported [238]. LPA also cross-talks with α1
adrenoceptors [239]. At physiological concentrations, LPA is capable of modulating opioid receptor
binding [240].
There are close interactions between two oncogenic lysolipids, LPA and S1P, in their overlapping
signaling pathways and/or directly in their receptors [241]. These two lipids can also cross-talk via
ATX [242,243]. Transforming growth factor beta (TGFβ) may play a role in the LPA–S1P cross-talk [244].
LPA upregulated expression of the cyclin-dependent kinase inhibitor p21(Waf1) in a TGFβ-dependent
manner [245]. Cross-talk between TNF-α and LPA results in the amplification of COX-2 protein
expression via a conserved protein kinase D (PKD)-dependent signaling pathway [246]. Hisano et al.
used a genome-wide CRISPR/dCas9-based GPCR signaling screen to identify that LPAR1 is an inducer of
S1PR1/β-arrestin coupling. This interaction promotes the porous junctional architecture of sinus-lining
lymphatic endothelial cells and enables efficient lymphocyte trafficking [247]. The functional link
between LPA and integrins was established. Active integrin β1 is required for migration of fibroblastic
cells [248]. Laminin, but not other extracellular matrix proteins, induces LPA production in ovarian
cancer cells via a β-integrin [164]. LPA induces αvβ6-integrin-mediated TGFβ activation via the
LPAR2 and the small Gq [249]. LPA upregulates integrins [250,251], and integrin signaling regulates
the nuclear localization and function of the LPAR1 in mammalian cells [252]. Moreover, LPA-induced
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RhoA activation integrates the functions of integrins [251,253] and integrin α6β4 promotes expression
of ATX in breast cancer cells [254]. Most noticeably, ATX directly binds to several integrins [91,255],
producing LPA close to the cell membrane [256] (Figure 4).
LPAR5 functions as an inhibitory receptor able to negatively regulate T-cell receptor (TCR)
signaling [204]. LPAR5 also inhibits B-cell receptor (BCR) signal transduction via a Gα12/13/Arhgef1
pathway [257]. On the other hand, LPA augments IL-13 secretion from T cells via induction of
submaximal T-cell activation [258].
The cross-talk can be mono- or bidirectional and can be either positive or negative cross-talk,
dependent on the type of interaction, the cell types, and the biological effects involved [259]. For example,
while LPA transactivates nerve growth factor signaling via the TrkA receptor, the latter also uses
a G-protein-mediated mechanism to regulate the p42/p44 MAPK pathway [260]. The bidirectional
regulation between LPA and integrins is mentioned above (Figure 4).
It is important to note that LPA is involved in several stem cell/cancer stem cell (CSC) signaling
pathways. The ATX–LPA signaling pathway is recognized as a critical new player in CSC [48]. LPA is
involved in classical stemness pathways, such as the Wnt, Notch, and Hippo pathways [189,261–265].
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2.2.4.2. The Molecular Mechanisms of LPA Cross-Talks
LPA cross-talks with other signaling molecules at many different levels with divergent mechanisms.
Firstly, interactions are through direct binding/interactions. Homo- and heterodimerization of LPA/S1P
receptors, ovarian cancer G protein coupled receptor-1 (OGR1) and GPR4, was shown using LacZ
complementation assays [266]. LPA receptors form homo- and heterodimers within the LPA receptor
subgroup and heterodimers with other receptors, such as S1PR1–3 and GPR4. Interestingly, it was
shown that LPA remarkably enhances, through the LPAR1/Gi protein, the OGR1-mediated vascular
actions to acidic pH [267]. These results suggest that targeting dimerization may be an effective way to
block the signaling mediated by the receptors. Although GPCR dimerization was known for many
years, this is an under-investigated area and warrants further investigation [266] (Figure 4).
Secondly, transactivation is mediated via enzymatic activities regulating phosphorylation and/or
ligand processing. LPA induces EGF receptor transactivation through metalloproteinase (MMP) and
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a disintegrin and metalloproteinase (ADAM)-catalyzed membrane shedding of heparin-binding EGF
and autocrine/paracrine activation of EGF [231,268,269], and EGF can also modulate LPAR1 function
and the phosphorylation state [268] (Figure 4).
Thirdly, an LPA-regulated transcriptome is involved. LPA regulates many cytokines, including
IL-6, IL-8, growth-regulated oncogene (GRO)-α [19,20,270,271], and cytokine leukemia inhibitory
factor (LIF) [241]. IL-6 mediates the LPA cross-talk between stromal and epithelial prostate cancer
cells [272]. LPA-induced macrophage migration inhibitory factor (MIF) promotes both tumor cell
growth and angiogenesis via both the Ras/MAPK and Ras–Akt/PI3K signaling pathways [273]. IL-6
exerts its biological activities through two molecules: IL-6R (IL-6 receptor) and gp130 [274]. Moreover,
gp130-mediated Janus kinase (JAK)/signal transducer and activation of transcription 3 (STAT3)
is required for ATX expression in adipocytes [177] (Figure 4). LPA stimulates the expression of
CSC-associated genes, including OCT4, SOX2, SOX9, ALDH1, and drug transporters [133,275,276],
with most of these gene products being functionally involved in CSC.
Fourthly, downstream signaling pathway interactions play important roles. The signaling
pathways involved in LPA cross-talk include, but are not limited to the PI3K/Ras [277], the
mitogen-activated protein kinase (MAP kinase) [277,278], the focal adhesion [119], the Wnt, integrin,
the Rho/Rock, and the YAP pathways [279,280], reactive oxygen species (ROS), the DNA repair pathway,
and the glycolytic pathway [27], as well as the Rho–cAMP interaction [281] (Figure 4).
Finally, other signaling molecules may regulate metabolic enzymes for LPA and other lipid
molecules. Neurotransmitters, cytokines, and growth factors regulate the activity of a key set
of lipid-metabolizing enzymes, such as phospholipases, to affect LPA and other lipid signaling
molecules [282]. In addition, an acylglycerol kinase that produces LPA modulates cross-talk with
EGFR in prostate cancer cells [283].
The targeting of one or more of these cross-talks and/or the major LPA downstream signaling
pathways may be critical and/or more efficient than targeting LPA or LPAR directly. For example,
the FDA recently approved the first PI3K inhibitor for breast cancer treatment. The challenges are
identifying one or more driver targets at the level of individual cancer type and individual patient.
2.2.5. Targeting Tumor–Stromal Interactions in the TME
Targeting the tumor-prone microenvironment gained increasing attention in recent years [7].
Although ATX can be produced directly by cancer cells, such as in melanomas, glioblastomas, and
thyroid tumors [95], it may be mainly produced by stroma cells, as ~40% of ATX in the body is
produced by adipocytes, and this is increased further by inflammation in obesity linked to insulin
resistance [95]. In addition, macrophage-derived phospholipase A2 (PLA2), which is a soluble PLA2,
produces extracellular LPA and is involved in EOC and associated with early relapse of EOC [284,285]
(Figure 5).
While S1P’s functions in the immune system were extensively studied, and the S1P receptor axis
represents an obligatory signal for trafficking of immune cells [34], the role of LPA in the immune
system is less studied [34]. LPA affects TCR and BCR as mentioned in Section 2.2.4.1, and LPA converts
monocytes into macrophages in both mice and humans [286] (Figure 5). In addition, ATX represents
a connecting point for both S1P and LPA, since it is an enzyme producing both S1P and LPA [287].
More interestingly, a recent study showed that S1P/S1PR4 and ATX/LPA/LPAR5,6 appear as critical axes
for immune infiltrates [34]. These were robust differences in sphingolipid/LPA-related checkpoints and
the drug response. Genes including CD68 (a monocyte/macrophage marker), LPAR3 (a LPA receptor),
SMPD1 (sphingomyelin phosphodiesterase 1 that converts sphingomyelin to ceramide), PPAP2B
(LPP3, a phosphatidic acid phosphatase, converting phosphatidic acid to diacylglycerol and LPA to
monoacylglecerol [288]), and SMPD2 (sphingomyelin phosphodiesterase 2, with lysophospholipase
activity) emerged as the most prognostically important markers. In particular, alignment of data across
a variety of malignancies (over 600 different neoplasm categories) revealed specific preference for
ovarian carcinoma [34]. It is interesting that ATX, LPAR1, and LPAR5 are higher in the immune-high
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tumor (Cd14-, Cd68-, Cd164-, and Cd3E-high) group, but LPAR2.3 are higher in the immune-low
group [34], suggesting the complex regulatory roles of the ATX–LPA axis in the tumor–immune
system interaction.Cancers 2019, 11, x 11 of 25 
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3. Conclusions
hile LPA and/or the ATX–LPA axis are generally accepted as important targets for cancer,
we are still facing several major obstacles to move targeting to clinical practice as presented above.
Personalized medicine is now well accepted conceptually to treat highly heterogenic diseases, such
as cancers. The complex LPA metabolism, its receptor, and its signaling systems suggest that
detecting signatures/networks, rather than individual gene/protein/lipid expression, from individual
patients will likely become necessary to develop effective treatments for highly heterogenic diseases,
such as cancer. Bioinformatics/systems biological analyses become very important to achieve
such goals, which provide unprecedented scale and depth of knowledge and perspectives in
cancer research, as well as directions for translational and clinical applications. These studies
use multi-modular integrative approaches consolidating large amount of data from gene expression
profiling, next-generation sequencing, -omics studies, prognostic/predictive modeling, and functional
studies for cancer [295,296]. The most prominent example is the Pan-cancer Atlas analyses organized
by the National Institute of Health (NIH), which is based on The Cancer Genome Atlas (TCGA)
data of over 11,000 tumors from 33 of the most prevalent forms of cancer, using comprehensive,
in-depth, and interconnected bioinformatics analyses (https://www.cell.co /pb-assets/consortiu /
pancanceratlas/pancani3/index.ht l?code=cell-site). One such study related to LPA identified novel
sphingolipid–LPA i une checkpoints and networks underlying tu or i une heterogeneity and
disease outco es, as entioned in the Section 2.2.5 [34]. This type of study holds great pro ise for
delivering novel stratifying and targeting strategies [34].
It is important to note that, although targeting LPA signaling appears to be an attractive approach
for cancer treatment, it is unlikely that this will be effective as monotherapy. One of the major challenges
in LPA targeting will be to discover the magic modalities to be effective in cancer treatment, which
are likely to be different for different cancers and even for different individuals. Synthetic lethality
studies led to the clinical benefits of using poly (ADP-ribose) polymerase (PARP) inhibitors in OC and
other cancers, which is a very significant step forward in the field [297]. Similar studies are urgently
needed for LPA targeting through logical and empirical screening. As an interesting note, accumulated
data suggest that LPA is a very strong inducer for cell migration, invasion, and tumor metastasis, but
a rather weak proliferation stimulus [4,23,25]. On the other hand, growth factors, such as EGF and
insulin growth receptor (IGF), possess strong cell proliferation, but rather weak chemotactic activities.
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Proper combinational inhibition of these two sets of critical activities in cancer cells simultaneously
may represent an effective strategy (Figure 4). Both in vitro and in vivo studies in these areas are highly
needed to move the field forward.
Taken together, although we are still facing a number of obstacles, the large body of data generated
from the last 3–4 decades from thousands of papers provided solid evidence and rationale to target the
LPA network. Rapid development of biotechnological tools for analyses of LPA, as well as its functions
and mechanisms, and for processing the vast amount of data provided and will continue to furnish
essentials for the field to leap ahead and eventually improve patient outcomes.
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